Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease

被引：0
|
作者：
Schmidt, Andrew Lachlan
Anton, Angelyn
Wong, Shirley S.
Azad, Arun
Kwan, Edmond Michael
Spain, Lavinia Anne
Torres, Javier
Muthusamy, Arunbalaji
Parente, Phillip
Parnis, Francis
Goh, Jeffrey C.
Joshua, Anthony M.
Pook, David William
Gibbs, Peter
Tran, Ben
Weickhardt, Andrew James
机构：
[1] Dept Med Oncol, Brisbane, Qld, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Australia
[3] Western Hosp, Brunswick, ME, Australia
[4] Monash Hlth, Dept Med Oncol, Melbourne, Australia
[5] Monash Univ, Melbourne, Australia
[6] Goulburn Valley Hlth, Shepparton, Australia
[7] Austin Hlth, Melbourne, Vic, Australia
[8] Eastern Hlth, Melbourne, Vic, Australia
[9] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia
[10] Adelaide Canc Ctr, Adelaide, SA, Australia
[11] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[12] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[13] Monash Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[14] Royal Melbourne Hosp, Melbourne, Vic, Australia
[15] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[16] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
78
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel
    Cushen, Samantha J.
    Power, Derek G.
    Murphy, Kevin P.
    McDermott, Ray
    Griffin, Brendan T.
    Lim, Marvin
    Daly, Louise
    MacEneaney, Peter
    Sullivan, Kathleen O'
    Prado, Carla M.
    Ryan, Aoife M.
    CLINICAL NUTRITION ESPEN, 2016, 13 : E39 - E45
  • [32] Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel
    Peltekian, Sophie
    Sajwani, Shellyza
    Wang, Xiang
    Kanji, Salmaan
    SUPPORTIVE CARE IN CANCER, 2023, 31 (05)
  • [33] Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel
    Sophie Peltekian
    Shellyza Sajwani
    Xiang Wang
    Salmaan Kanji
    Supportive Care in Cancer, 2023, 31
  • [34] PRACTICE PATTERNS IN MANAGEMENT OF HORMONE SENSITIVE METASTATIC AND CASTRATE-RESISTANT NON-METASTATIC PROSTATE CANCER
    Joyce, Daniel D.
    Sharma, Vidit
    Zganjar, Andrew
    Kwon, Eugene D.
    Karnes, R. Jeffrey
    JOURNAL OF UROLOGY, 2022, 207 (05): : E457 - E457
  • [35] Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer
    Ang, Jia Wei
    Tan, Min-Han
    Tay, Miah Hiang
    Toh, Chee Keong
    Ng, Quan Sing
    Kanesvaran, Ravindran
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2017, 46 (05) : 195 - 201
  • [36] Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
    Vankayala, Hema M.
    Heilbrun, Lance K.
    Dobson, Kimberlee
    Stark, Karri
    Li, Jing
    Smith, Daryn W.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Strauss, Julius
    Chun, Guinevere
    Couvillon, Anna
    Harold, Nancy
    Chen, Clara
    Dawson, Nancy Ann
    Apolo, Andrea Borghese
    Steinberg, Seth M.
    Trepel, Jane B.
    Wright, John Joseph
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Treatment outcomes of patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC) on first line docetaxel chemotherapy at University Malaya Medical Centre
    Khoo, J. Y-Y
    Alip, A.
    Saad, M.
    Ong, T. A.
    BJU INTERNATIONAL, 2016, 118 : 32 - 32
  • [39] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [40] Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
    Thomson, David
    Charnley, Natalie
    Parikh, Omi
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) : 1040 - 1041
12345